Vestcor Inc Neurocrine Biosciences Inc Transaction History

Vestcor Inc

$2.96 Billion
Q2 2024

A detailed history of Vestcor Inc transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Vestcor Inc holds 25,092 shares of NBIX stock, worth $2.89 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares

25,092

Previous 25,092 -0.0%

Holding current value

$2.89 Million

Previous $3.46 Million 0.2%

% of portfolio

0.12%

Previous 0.12%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$130.4 - $143.74 $33,643 - $37,084	-258 Reduced 1.02%	25,092 $3.46 Million
Q4 2023 Feb 14, 2024	BUY	$106.07 - $132.76 $104,054 - $130,237	981 Added 4.03%	25,350 $3.34 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $670,174 - $834,688	7,128 Added 41.34%	24,369 $2.74 Million
Q2 2023 Aug 15, 2023	BUY	$89.53 - $104.87 $340,124 - $398,401	3,799 Added 28.26%	17,241 $1.63 Million
Q4 2022 Feb 15, 2023	BUY	$106.72 - $127.06 $685,782 - $816,487	6,426 Added 91.59%	13,442 $1.61 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $441,744 - $517,488	4,800 Added 216.61%	7,016 $745,000
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $54,265 - $71,650	716 Added 47.73%	2,216 $216,000
Q1 2022 May 16, 2022	SELL	$72.45 - $94.81 $137,365 - $179,759	-1,896 Reduced 55.83%	1,500 $141,000
Q4 2021 Feb 15, 2022	SELL	$79.65 - $106.22 $38,391 - $51,198	-482 Reduced 12.43%	3,396 $289,000
Q3 2021 Nov 15, 2021	SELL	$86.18 - $99.03 $15,340 - $17,627	-178 Reduced 4.39%	3,878 $372,000
Q2 2021 Aug 16, 2021	BUY	$89.43 - $102.27 $141,031 - $161,279	1,577 Added 63.61%	4,056 $395,000
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $210,938 - $323,162	2,479 New	2,479 $302,000

Others Institutions Holding NBIX

# of Institutions

641

Shares Held

95.3M

Call Options Held

661K

Put Options Held

227K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vestcor Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vestcor Inc with notifications on news.

Account